288 related articles for article (PubMed ID: 29338536)
21. P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries.
Zeymer U; Widimsky P; Danchin N; Lettino M; Bardaji A; Barrabes JA; Cequier A; Claeys MJ; De Luca L; Dörler J; Erlinge D; Erne P; Goldstein P; Koul SM; Lemesle G; Lüscher TF; Matter CM; Montalescot G; Radovanovic D; Sendón JL; Tousek P; Weidinger F; Weston CF; Zaman A; Andell P; Li J; Jukema JW;
Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):229-43. PubMed ID: 27533946
[TBL] [Abstract][Full Text] [Related]
22. A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs.
Fayaz SM; Rajanikant GK
Curr Pharm Des; 2012; 18(12):1625-34. PubMed ID: 22360514
[TBL] [Abstract][Full Text] [Related]
23. International Expert Consensus on Switching Platelet P2Y
Angiolillo DJ; Rollini F; Storey RF; Bhatt DL; James S; Schneider DJ; Sibbing D; So DYF; Trenk D; Alexopoulos D; Gurbel PA; Hochholzer W; De Luca L; Bonello L; Aradi D; Cuisset T; Tantry US; Wang TY; Valgimigli M; Waksman R; Mehran R; Montalescot G; Franchi F; Price MJ
Circulation; 2017 Nov; 136(20):1955-1975. PubMed ID: 29084738
[TBL] [Abstract][Full Text] [Related]
24. Expert Opinion on P2Y12 Inhibitors Use in Management of Acute Coronary Syndromes: Focus on Ticagrelor.
Sathyamurthy I; Hiremath MS; Sawhney JP; Chandra S; Mishra H; Ponde CK; Ray S; Hardas S; Sathe S; Rath PC; R B; Navasundi GB; Magarkar V; Makhale CN; Banerjee S; Vaidyanathan PR; Sen AK; Bp P; C SO
J Assoc Physicians India; 2021 Oct; 69(10):11-12. PubMed ID: 34781659
[TBL] [Abstract][Full Text] [Related]
25. De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Guo C; Li M; Lv YH; Zhang MB; Wang ZL
Platelets; 2020; 31(1):15-25. PubMed ID: 30759033
[TBL] [Abstract][Full Text] [Related]
26. New antiplatelet agents in the treatment of acute coronary syndromes.
Sabouret P; Taiel-Sartral M
Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
[TBL] [Abstract][Full Text] [Related]
27. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
28. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
Roffman DS
J Pharm Pract; 2016 Jun; 29(3):239-49. PubMed ID: 25660584
[TBL] [Abstract][Full Text] [Related]
29. Ticagrelor: a review of its use in adults with acute coronary syndromes.
Dhillon S
Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
[TBL] [Abstract][Full Text] [Related]
30. Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis.
Shpigelman J; Proshkina A; Daly MJ; Cox D
Curr Cardiol Rep; 2023 Jul; 25(7):693-710. PubMed ID: 37261665
[TBL] [Abstract][Full Text] [Related]
31. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Packard KA; Campbell JA; Knezevich JT; Davis EM
Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
[TBL] [Abstract][Full Text] [Related]
33. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
[TBL] [Abstract][Full Text] [Related]
34. Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.
Galli M; Franchi F; Rollini F; Cavallari LH; Capodanno D; Crea F; Angiolillo DJ
Expert Rev Clin Pharmacol; 2021 Aug; 14(8):963-978. PubMed ID: 33993817
[TBL] [Abstract][Full Text] [Related]
35. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
[TBL] [Abstract][Full Text] [Related]
36. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
[TBL] [Abstract][Full Text] [Related]
37. Emerging oral antiplatelet therapies for acute coronary syndromes.
Pollack CV
Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
[TBL] [Abstract][Full Text] [Related]
38. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
39. Dual Antiplatelet Therapy De-escalation Strategies.
Sinnaeve PR; Adriaenssens T
Am J Cardiol; 2021 Apr; 144 Suppl 1():S23-S31. PubMed ID: 33706987
[TBL] [Abstract][Full Text] [Related]
40. Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors.
Howell LA; Stouffer GA; Polasek M; Rossi JS
Expert Rev Clin Pharmacol; 2015; 8(4):411-21. PubMed ID: 26092217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
